drug_type
RELEVANT_DRUG
intervention_type
Genetically modified autologous TCR-T cell therapy
drug_description
Autologous T lymphocytes genetically engineered to express a T-cell receptor specific for an HPV16 E7 peptide presented by HLA-A*02:01; infused to recognize and kill E7-positive tumor cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Receptors, Antigen, T-Cell
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T lymphocytes genetically engineered to express an HLA-A*02:01–restricted T-cell receptor specific for an HPV16 E7 peptide. Upon encountering E7–HLA complexes on tumor cells, the TCR-T cells activate via TCR signaling and mediate cytotoxic killing through perforin/granzyme release and cytokine secretion, eliminating E7-positive cancer cells.
drug_name
CRTE7A2-01 TCR-T cells
nct_id_drug_ref
NCT06358053